'Not a tolerable situation': Patient groups take aim at CMS over Alzheimer's coverage decision

By Politico
| January 17, 2022

Their goal is to strong arm CMS into covering Aduhelm, the $28,200-per-year drug, for far more people.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

A new personal protective equipment manufacturing company is set to open in Cincinnati next year. ...